Construction of [<sup>89</sup>Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells-Reference-Cited by-同舟云学术

Construction of [⁸⁹Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells

Published:2024-06-28 Issue:8 Volume:21 Page:3992-4003
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Ding Lixin¹,Wang Feng¹,Wang Zilei¹,Pan Yongxiang¹,Liu Teli¹,Cheng Liansheng²,Liu Wenting²,Ding Kuke³,Zhu Hua¹^ORCID,Yang Zhi¹^ORCID

Affiliation:

1. State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China

2. Hefei HankeMab Biotechnology Limited, Hefei, Anhui 230088, China

3. Office for Public Health Management, Chinese Center for Disease Control and Prevention, Beijing 102206, China

Funder

Beijing Municipal Health Commission

Organization Department of the Central Committee of the Communist Party of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.4c00343

Reference42 articles.

1. Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge

2. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

3. A decade of immune-checkpoint inhibitors in cancer therapy

4. Immune checkpoint signaling and cancer immunotherapy

5. Resistance to PD1/PDL1 checkpoint inhibition